Maximizing therapeutic potential of poorly soluble small molecules
Products and Technology
VeraMorph has developed a proprietary oral drug delivery platform that we are leveraging to help companies improve and accelerate clinical translation of poorly soluble lead compounds and build a specialty drug product portfolio comprised of clinically-differentiated oral versions of approved drugs.
VeraMorph is led by a small team of experienced and passionate entrepreneurs and executives with drug delivery and product design expertise.
We are actively seeking driven and skilled chemists, engineers, and scientists to build our R&D team with a collaborative and fast-pace lab environment.
VeraMorph CEO, Doug Godfrin, will present on the company's platform technology at AAPS PharmSci 360
May 15, 2023
The presentation will be delivered on Tuesday, October 24 in the Formulation and Delivery Track to an audience of scientists and executives with a focus on drug delivery technologies.
VeraMorph's platform technology has been accepted into the FDA Novel Excipient Review Program
July 29, 2022
The FDA Novel Excipient Review Program will help accelerate de-risking the regulatory pathway for VeraMorph's platform technology by providing for feedback prior to regulatory submissions.